Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103453 | 0.72 | — | — | |
| SCHEMBL5024897 | 0.72 | — | — | |
| SCHEMBL8903927 | 0.71 | — | — | |
| SCHEMBL846155 | 0.70 | — | — | |
| SCHEMBL102982 | 0.70 | — | — | |
| Ethyl Nitrosourea SCHEMBL77485 | 0.70 | — | — | |
| SCHEMBL87564 | 0.70 | — | — | |
| SCHEMBL4460224 | 0.67 | ALDH1A1 (0.36) | TSHRMEN1ABCB11ALDH1A1GSR | |
| SCHEMBL103666 | 0.67 | CES2 (0.38) | TSHRMEN1ABCB11ALDH1A1GSR | |
| SCHEMBL103983 | 0.67 | TSHR (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3395 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028400-A1 | ANTI-ROR1 ANTIBODY AND USE THEREOF | AIMED BIO INC (KR) | 2026-01-29 | — | — | US | claimed |
| US-20250270320-A1 | ANTI-PD-1 ANTIBODY AND USES THEREOF | EUTILEX CO., LTD. (KR) | 2025-08-28 | — | — | US | claimed |
| EP-4563597-A1 | ANTI-ROR1 ANTIBODY AND USE THEREOF | AIMED BIO INC. (KR) | 2025-06-04 | — | — | EP | claimed |
| US-20250171745-A1 | ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S) | DNATRIX INC (US) | 2025-05-29 | — | — | US | claimed |
| US-20250032629-A1 | NOVEL NUCLEOLIN-BINDING PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2025-01-30 | — | — | US | claimed |
| CN-114716548-B | Anti-FGFR 3 antibodies and uses thereof | (株)爱恩德生物 | 2024-11-05 | — | — | CN | claimed |
| US-20240216492-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | CV BIOMANUFACTURING, LLC | 2024-07-04 | — | — | US | claimed |
| EP-4329878-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | Dnatrix, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| WO-2024025343-A1 | ANTI-ROR1 ANTIBODY AND USE THEREOF | (주)에임드바이오 | 2024-02-01 | — | — | WO | claimed |
| EP-4276112-A1 | ANTI-FGFR3 ANTIBODY AND USE THEREOF | AIMED BIO INC. (KR) | 2023-11-15 | — | — | EP | claimed |
| WO-2007012133-A1 | THERAPEUTIC PROTOCOLS USING HYALURONAN | ALCHEMIA ONCOLOGY PTY LIMITED (AU) | 2007-02-01 | — | — | WO | claimed |
| US-20050215498-A1 | Method for the protection of endothelial and epithclial cells during chemotherapy | KLINIKUM DER UNIVERSITAET REGENSBURG (DE) | 2005-09-29 | — | — | US | claimed |
| US-6932777-B2 | Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2005-08-23 | — | — | US | claimed |
| US-20040072786-A1 | Antisense oligonucleotide inhibition of ras | MONIA BRETT P (US) | 2004-04-15 | — | — | US | claimed |
| US-6656918-B2 | Contacting the ductal epithelium of the exocrine gland with epithelium destroying agents such as ethanol and vaccinia virus | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2003-12-02 | — | — | US | claimed |
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | claimed |
| US-20030013670-A1 | Antisense oligonucleotide inhibition of ras | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| EP-0668782-B1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | UNIV TEMPLE (US) | 2001-04-11 | — | — | EP | claimed |
| EP-0668782-A1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1995-08-30 | — | — | EP | claimed |
| WO-1994008625-A1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1994-04-28 | — | — | WO | claimed |